Recent studies of the p53 tumor suppressor locus (designated TP53) in primary hepatocellular carinoma (PHC) have identified a high frequency of codon 249 mutations. Due to the geographic location from which the samples were obtained and the substitution observed, the mutation was sug- (PHC) and have elicited speculation of a link with aflatoxin B1 (AFB1) exposure in tumors ofthese types (1, 2). These studies have found that 50% oftumors show a mutation in the p53 gene ("p53 mutation"). In all cases examined, a G-to-T mutation, which resulted in an amino acid substitution, was observed. This type of mutation is consistent with nucleotide substitutions associated with AFB1 exposure (3). Most provocative among these findings was the observation that 42% (11 of 26) of the tumors examined contained a codon 249 mutation.
frequency previously reported. Codon 249 mutations occurred at a much lower frequency than previously reported (2 of 107 samples examined). These results suggest that changes in DNA encoding p53 may not represent primary oncogenic effects but instead represent genetic changes related to tumor progression.
gh AFB, levels may facilitate the generation of these progressional changes, but not by inducing a specific p53 gene mutation at codon 249 as previously reported.
Recent molecular genetic studies have implicated the p53 tumor suppressor gene (designated TP53) as playing a key role in the genetic etiology of primary hepatocellular carcinoma (PHC) and have elicited speculation of a link with aflatoxin B1 (AFB1) exposure in tumors ofthese types (1, 2) . These studies have found that 50% oftumors show a mutation in the p53 gene ("p53 mutation"). In all cases examined, a G-to-T mutation, which resulted in an amino acid substitution, was observed. This type of mutation is consistent with nucleotide substitutions associated with AFB1 exposure (3) . Most provocative among these findings was the observation that 42% (11 of 26) of the tumors examined contained a codon 249 mutation.
In an attempt to determine the generality ofthis phenomena, we have examined a large collection of tumors from geographically and ethnically diverse sources. The frequency of codon 249 p53 mutations was evaluated by using the PCR/restriction digest method of Bressac et al. (1) . Mutations at other locations in the p53 gene were assessed by using a G+C-rich sequence (GC-clamp) in conjunction with denaturing gradient gel electrophoresis (DGGE). Direct PCR sequencing was used to identify specific nucleotide substitutions detected by DGGE. (4) Ja (4) AN (7) AN (7) AN (7) AN (7) AN (7) AN (7) AN (7) AB (8) AB (8) AB (8) AB (8) AB (8) AB (8) AB (8) AB (8) AB (8) ? (6) ? (6) ? (6) ? (6) Ca (5) ? (5) Ca (5) Ca (5) Ca (5) Ca (5) ? (5) ? (4) ? (4) ? (4) ? (4) Other  922  923  924  925  926  927  928  929  935  936  941  942  759  7%  798  799  800  801  802  804  807  808  810  811  814  815  816  817  818  819  820  821  822  823  824  825  826  827  828  829  830  833  834  836  837  838  839  840  841  842  843  847  848  849 Ch (1) Ch (1) Ch (1) Ch (1) Ch (1) Ch (1) Ch (1) Ch (1) Ch (1) Ch (1) Ch (1) Ch (1) Ch (2) Ch (2) Ch (2) Ch (2) Ch (2) Ch (2) Ch (2) Ch (2) Ch (2) Ch (2) Ch (2 Proc. Nati. Acad. Sci. USA 89 (1992) 7 (fragment 3), and exons 8 and 9 (fragment 4). The primers used and relative regions of the p53 locus amplified are summarized in Fig. 1 . For the purpose of DGGE analysis a G+C-rich sequence (GC clamp) of 40 base pairs was added to the 5' end of one primer of each set (8, 9) . PCR amplification was performed with minor modifications of a previously reported protocol (9) . Briefly, 500 ng of DNA was mixed with 50 pmol of each nucleotide primer and 37. GC-clamp DGGE. Each PCR amplified product (=15 Ag) was analyzed on a denaturing gradient gel as described (8, 9) . Briefly, an 8% polyacrylamide gel containing a linear gradient of DNA denaturants (100%6 denaturant is defined as 7 M urea/40% formamide) was prepared with a Hoefer Series SG gradient maker. Gradients of 60-80%, 40-70%o, and 35-65% were used, respectively, for fragments 1, 2, and both 3 and 4. Appropriate gradient conditions were determined experimentally with perpendicular DGGE (10) . Samples were loaded onto the gel and electrophoresed at 150 V at 60°C constant temperature for 11 hr for fragment 1, 8 hr for fragment 2, 6 hr for fragment 3, and 8 hr for fragment 4 . The gel was then stained with ethidium bromide and photographed. Base changes were identified by the presence of one or more new bands or a shift in position of a band compared with nontumor tissue samples from the same individual.
METHODS
Direct sequencing ofPCR products. A subset of samples identified as containing a base change within an exon were sequenced to confirm the DGGE result and to identify the precise base change. Direct sequencing of the PCR-amplified product was performed by using a modification of previously described protocols (11) . Briefly, the remaining PCR amplified product was run on a 1.5% preparative agarose gel to separate the amplified product from remaining primer. The fragment was recovered from the agarose by using a Costar 0.22-mm cellulose acetate centrifuge filter unit. The DNA was precipitated with ethanol and resuspended in 15 p1 of the sample by using a United States Biochemical sequencing kit according to the manufacturer's instructions, except that 10 pmol of primer was used. Sequence analysis was on a 6% polyacrylamide sequencing gel.
RESULTS
A total of 107 tumors was examined for the codon 249 G-to-T mutation detected by Hae III digestion of the exon 7 PCR product (see Table 1 ). Tumors with mutations in this codon are not cleaved by Hae III. Only two of the 107 tumors demonstrated the previously described mutation (Fig. 2) . One sample (number 799) was obtained from the Xian area of the People's Republic of China, an area with a relatively low AFB1 exposure frequency (12) , and the other (number 935) was from an area with endemic AFB1 exposure (Shanghai). It is worth noting that in sample 799, the tumor appeared to be heterozygous for the codon 249 mutation. This overall frequency of codon 249 mutation is significantly lower than that observed in earlier studies (V2 = 38.79, P < 0.0001). The frequency of 249 mutations in the Shanghai region is also significantly lower than in earlier reports (V2 = 4.39, P = 0.04).
A subset of the tumors without codon 249 mutations from each of the ethnic groups and geographic locations was next analyzed for p53 mutations in exons 5-9 by DGGE. Exons 5-9 represent the most common locations of p53 mutations. These results are summarized in Table 1 . Of the 51 tumors evaluated, 10 p53 DNA variants were observed (18%): 2 of the changes were observed in exon 6, 7 were observed in exon 7 (Fig. 3) , and 1 case involved both an exon 6 and 8 change. However, the exon 6 change was also observed in the sample ofuninvolved liver adjacent to the tumor. Sequencing of this change indicated that the change was an A-to-G transition in the third base position of codon 213, which does not result in an amino acid substitution. Four of the exon 7 changes have been sequenced (Fig. 4) . Mutations that result in amino acid substitutions were observed in codons 237, 248, 258, and 273. In three cases, a G-to-A transition was observed that would result in a substitution of isoleucine for methionine, glutamine for arginine, and histadine for arginine in codons 237, 248, and 273, respectively. In codon 258 a G-to-C change, which resulted in a substitution of glutamine for glycine, was observed.
DISCUSSION
Epidemiologic studies have identified a number of environmental factors that markedly increase risk of PHC. Foremost among these is chronic infection with the HBV (13, 14) . Concordance of PHC incidence and environmental levels of the carcinogen AFB1 led to the suggestion that AFB1 exposure may also be an important risk factor (15) (16) (17) Overall, the p53 mutation rate was also much lower than previously described, and a greater variety of mutations was identified. In the current study, 8 of 50 tumors examined by DGGE showed a mutation in exons 5-8 at the p53 locus. Finally, of the 5 samples sequenced, no G-to-T changes were observed. The substitution patterns observed here are more consistent with p53 mutation patterns observed in other cancers. It is important to note that the current sample differs from the previously reported results in two key aspects. First, while 21 samples were obtained from regions with high AFB1 contamination (Shanghai, the People's Republic of China, and South Africa), the majority of samples were obtained from areas with low environmental levels of AFB1. The ethnic composition of the current population was also more diverse than those in previous investigations. Among the samples obtained from regions with high environmental levels of AFB1, only one codon 249 mutation was observed. However, the 12 tumors obtained from the Shanghai region of China examined by DGGE showed the highest frequency of p53 mutations. Of the 12 tumors, 3 showed mutations in exon 7. Two of the samples were obtained from an Alaskan multicase family (4) . A test was made that familial PHC may be due to germ-line p53 mutations in a manner similar to the Li-Fraumeni syndrome (20) . No p53 mutations were observed in exons [5] [6] [7] [8] Fig. 4 The failure to observe a high frequency of codon 249 mutations does not preclude the postulated role of AFB1 in PHC etiology. The observation of modest frequency of p53 mutations among the tumors obtained from the high AFB1 region of China continues to provide correlational support for the role of AFB1. However, the absence of G-to-T mutations and the multitude of other associated risk factors such as the drinking water source (27) would suggest that other environmental cofactors may be important in generating p53 mutations. Perhaps more importantly, the absence of p53 mutations from the majority of PHC samples in the current study calls into question their etiologic importance. The histopathologies of PHC samples from various geographic locations have not been observed to differ. However, the observed difference in p53 mutations suggests that PHC has different underlying genetic etiologies in different regions of the world. Alternatively, the p53 mutations observed may not represent primary oncogenic effects and instead represent genetic changes due to tumor progression. AFB1 exposure may facilitate the generation of these progressional changes.
